Nebius Group NV vs Regeneron Pharmaceuticals Inc — how do they compare? Nebius Group NV trades at $223.64 (market cap $49.06B), while Regeneron Pharmaceuticals Inc trades at $794.9 (market cap $82.06B). The key difference: Regeneron Pharmaceuticals Inc is the larger of the two by market cap, and Regeneron Pharmaceuticals Inc pays a 0.47% dividend while Nebius Group NV pays none. Which is the better fit depends on your goals.
| NBIS | REGN | |
|---|---|---|
Market Cap | $49.06B | $82.06B |
Sector | Technology | Health |
52-Week High | $286.69 | $812.27 |
52-Week Low | $64.06 | $555.51 |
Enterprise Value | $49.26B | $76.77B |
Dividend Yield | — | 0.47% |
Trailing returns across standard periods
Latest headlines on both assets
Nebius Group N.V. is a technology company specializing in AI, machine learning, and cloud computing solutions. The company provides a range of enterprise-level cloud services, including large-scale data processing, advanced analytics, and AI model development and deployment. Nebius Group focuses on serving businesses that require high-performance, scalable, and secure infrastructure to handle complex computational tasks and accelerate their digital transformation.
Read more on NBIS →Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →